Clinical Trial Update: A Study of ABM-1310 in Patients With BRAF V600-Mutant Relapsed and Drug Resistant Primary Malignant Brain Tumors [Phase 1]

View source ↗

Summary

A Phase 1 trial of ABM-1310 for BRAF V600-mutant relapsed and drug-resistant primary malignant brain tumors has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Brain Tumor

Drugs mentioned

• ABM-1310

Snippet

Sponsor: ABM Therapeutics Shanghai Company Limited | Conditions: Primary Malignant Brain Tumor | Phase 1 | Status: TERMINATED